8 completed, 4 active not recruiting, 4 unknown, 1 recruiting. 8 Phase 2, 3 Not applicable, 3 Phase 1, 2 Phase 3, 1 Phase 4.
Follow The Aurum Institute NPC: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Confirmatory Trial of Adjunctive NAC to Prevent Post Tuberculosis Lung Disease N-Acetyl Cysteine (NAC), Standard TB treatment - Tuberculosis (TB) | Not applicable | Recruiting | The Aurum Institute NPC | 242 | 2025-04-28 | 2025-04-30 |
| Introduction of Dispersible 3HP Formulations for TB Preventive Treatment in Children: a Multi-country Evaluation TB - Tuberculosis, Household Contact | Unknown | The Aurum Institute NPC | 1200 | 2024-08-01 | 2024-07-19 | |
| Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV Rifapentine, Isoniazid - HIV Seropositivity, Pregnancy | Phase 1 / Phase 2 | Active not recruiting | The Aurum Institute NPC | 252 | 2024-01-17 | 2025-12-12 |
| A Pan-TB Regimen Targeting Host and Microbe Sutezolid, N-acetyl cysteine, Pretomanid - Tuberculosis | Phase 2 / Phase 3 | Active not recruiting | The Aurum Institute NPC | 352 | 2023-07-28 | 2025-05-28 |
| Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients Daily rifapentine and isoniazid for 4 weeks, Weekly rifapentine and isoniazid for 12 weeks - HIV Seropositivity, Tuberculosis | Phase 4 | Active not recruiting | The Aurum Institute NPC | 1000 | 2023-07-19 | 2025-12-12 |
| Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS) Dolutegravir, 3HP - Tuberculosis, HIV | Phase 1 / Phase 2 | Active not recruiting | The Aurum Institute NPC | 92 | 2023-05-24 | 2025-12-12 |
| Phase 2a Trial to Evaluate Safety and Immunogenicity of COVID-19 Vaccine Strategies in HIV-infected/Uninfected Adults. Ad26.COV2.S (VAC31518, JNJ-78436735) Vaccine, SARS-CoV-2 rS (CovovaxTM), BNT162b2 (Pfizer) - COVID-19 | Phase 2 | Unknown | The Aurum Institute NPC | 694 | 2022-07-25 | 2024-07-15 |
| Tuberculosis as a Risk Factor for a Worse Outcome Post-Sars-CoV-2 Infection COVID-19, Tuberculosis | Completed | The Aurum Institute NPC | 157 | 2021-03-23 | 2023-01-11 | |
| Adjunctive NAC in Adult Patients With Pulmonary Tuberculosis N-acetyl cysteine - Tuberculosis, Pulmonary | Phase 2 | Completed | The Aurum Institute NPC | 110 | 2019-03-01 | 2024-11-12 |
| Study to Evaluate H56:IC31 in Preventing Rate of TB Recurrence H56:IC31, Placebo - Tuberculosis, Pulmonary | Phase 2 | Completed | International AIDS Vaccine Initiative | 831 | 2019-01-31 | 2026-02-24 |
| Safety Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine and Isoniazid or Standard Isoniazid Preventive Therapy in HIV+ Patients (DOLPHIN & DOLPHIN TOO) 3HP plus DTG +2NRTIs - Respiratory Tract Infections, HIV Infections | Phase 1 / Phase 2 | Completed | The Aurum Institute NPC | 135 | 2018-01-18 | 2023-02-02 |
| TB Sequel: Pathogenesis and Risk Factors of Long-term Sequelae of Pulmonary TB No Intervention, and Observational Study - Respiratory Tract Infections, Tuberculosis, Pulmonary | Unknown | The Aurum Institute NPC | 1500 | 2017-09-22 | 2021-01-13 | |
| Evaluation of the Effect of 3HP vs Periodic 3HP vs 6H in HIV-Positive Individuals rifapentine + isoniazid, Isoniazid - Tuberculosis, HIV | Phase 3 | Completed | The Aurum Institute NPC | 4027 | 2016-11-01 | 2019-10-30 |
| TB Host Directed Therapy Everolimus 0.5 MG, Auranofin 6 MG, Vitamin D3 - Tuberculosis | Phase 2 | Unknown | The Aurum Institute NPC | 200 | 2016-11-01 | 2019-01-10 |
| The Evidence for Contraceptive Options and HIV Outcomes Trial DMPA, LNG, Copper IUD - HIV, Contraception | Not applicable | Completed | FHI 360 | 7830 | 2015-12-14 | 2019-08-20 |
| An Implementation Science Study Investigating Profiles of Men Interested in MMC Exclusive Intervention Strategy - Medical Male Circumcision | Completed | The Aurum Institute NPC | 2817 | 2014-04-01 | 2016-01-28 | |
| Thol'Impilo: Bringing People Into Care Point of care CD4 testing, Care Facilitation, Transport support - HIV | Not applicable | Completed | The Aurum Institute NPC | 2398 | 2012-06-01 | 2016-07-20 |
Tuberculosis (8) · Tuberculosis, Pulmonary (3) · COVID-19 (2) · HIV Infections (2) · HIV Seropositivity (2) · Latent Tuberculosis (2) · Respiratory Tract Infections (2) · Post-Acute COVID-19 Syndrome (1) · Recurrence (1) · Reinfection (1)
Acetylcysteine (3) · Isoniazid (3) · rifapentine (2) · Ad26COVS1 (1) · Auranofin (1) · BNT162 Vaccine (1) · CC-11050 (1) · Cholecalciferol (1) · Everolimus (1) · Intrauterine Devices, Copper (1) · Levonorgestrel (1) · N,N-dimethyl-4-anisidine (1) · Observation (1) · PNU-100480 (1) · Vaccines (1)
South Africa (14) · Tanzania (4) · Mozambique (3) · The Gambia (2) · Eswatini (1) · India (1) · Indonesia (1) · Kenya (1) · Zambia (1)
Andrea Rachow, MD (1) · Andrea Rachow, PhD, med (1) · Dr Vaneshree Govender (1) · Gavin Churchyard (1) · Gavin Churchyard, MBBCh, PhD (1) · Gavin J Churchyard (1) · Gavin J Churchyard, MBBCh PhD (1) · Marissa Russell (1) · Nicole Salazar-Austin (1) · Prof Gavin Churchyard, PhD (1) · Professor Robert Wallis, MD (1) · Robert S Wallis, MD,FIDSA (1) · Robert Wallis (1) · Salome Charalambous, MBBCH, PhD (1)
PMID 28471840, PMID 30005663, PMID 30616617, PMID 31204114, PMID 32240629, PMID 32396700, PMID 33740465, PMID 33898953, PMID 34126052, PMID 34158082, PMID 34424730, PMID 34910143, PMID 35263421, PMID 35657948, PMID 35669313, PMID 35941737, PMID 35972853, PMID 36622148, PMID 38459552, PMID 39085989, PMID 39189858, PMID 40056922, PMID 40349709, PMID 41690324, PMID 41749341, PMID 42482138